Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.
CAS Registry Number
18683-91-5
Molecular formula
C13H18Br2N2O
Molecular weight
378.1 g/mol
Drug class
Mucolyticsecretolytic and mucokinetic agent (bromhexine metabolite)
Mechanism of action
The precise mechanism is not fully elucidated. Ambroxol increases serous respiratory secretion, stimulates ciliary activity and mucociliary clearance, and activates pulmonary surfactant production, helping reduce mucus viscosity and facilitate expectoration.
Indications / reported uses
Expectorant use in acute and chronic respiratory conditions with abnormal viscid mucus, where authorised
Lozenge formulations may be used for sore throat; injectable uses and indications differ by product and jurisdiction
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
ERA assessment scope
Project-specific environmental risk assessment support
The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.
Phase I exposure screening and trigger evaluation.
Environmental fate and ecotoxicity review, with Phase II work where required.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope
Environmental Risk Assessment (ERA)
ReguSight provides project-specific support for the Ambroxol Environmental Risk Assessment (ERA) (the Ambroxol ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.
Assessment may cover
Product, active-substance identity, formulation, route and intended-market review.
Phase I environmental exposure screening and applicable trigger evaluation.
Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
Data-gap analysis, study strategy, assumptions and scientific reporting.
The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.